Gastroenterology
Latest news
416 articles · 20 / page
Minor Papillotomy for Pancreas Divisum: The SHARP Trial Challenges Decades of Endoscopic Practice
The SHARP randomized clinical trial finds that minor papillotomy does not significantly reduce the risk of recurrent acute pancreatitis in patients with pancreas divisum. These results challenge long-standing clinical practices and emphasiz
Incident Splenomegaly: Defining Clinical Thresholds for Hematologic Cancer and Liver Disease Risk
This large-scale prospective cohort study identifies specific spleen length and volume thresholds that significantly increase the 5-year risk of hematologic malignancies and liver disease, providing a data-driven framework for clinical work
Berberine Improves Lipid Profiles and Inflammation but Fails to Reduce Visceral and Liver Fat in MASLD
The BRAVO randomized clinical trial demonstrates that while 1 g/d of berberine significantly lowers LDL-C and hs-CRP in individuals with obesity and MASLD, it does not impact visceral adipose tissue area or liver fat content over a six-mont
Mediterranean Diet Outperforms Traditional Dietary Advice for Irritable Bowel Syndrome: A Landmark Randomized Trial
A randomized clinical trial published in the Annals of Internal Medicine reveals that the Mediterranean diet is superior to traditional dietary advice for managing IBS symptoms, offering a nutrient-dense, sustainable first-line intervention
Interactive Mobile Coaching Improves Long-Term Quality of Life and Symptom Management After Gastrectomy
A randomized controlled trial demonstrates that early interactive human coaching via a mobile app improves long-term quality of life, reduces dyspnea, and eases eating restrictions in postgastrectomy patients, particularly among younger and
Preoperative Nutritional Support Significantly Reduces Postoperative Enterocolitis in Children with Hirschsprung Disease: A Multicenter Randomized Controlled Trial
A multicenter RCT demonstrates that preoperative nutritional support reduces the incidence of Hirschsprung-associated enterocolitis (HAEC) from 29.09% to 7.27%, offering a critical strategy for improving surgical outcomes in pediatric patie
Is 2 Liters of PEG Necessary? Simplified Water Prep Proves Effective for Crohn’s Capsule Endoscopy
A randomized trial demonstrates that a simplified bowel preparation using clear liquids and water offers comparable diagnostic yield and cleanliness to PEG-based regimens for Crohn’s disease capsule endoscopy, while significantly improving
Rifaximin Demonstrates Superior Adherence and Faster Symptom Relief Compared to Low FODMAP Diet in Irritable Bowel Syndrome
Clinical trials reveal that Rifaximin provides faster symptom relief and significantly better adherence than the low FODMAP diet in IBS patients, while also potentially restoring lactase activity in those with small intestinal bacterial ove
CYTOscore: A Triple-Cytokine Signature Predicts Survival and Response to Chemoradiotherapy Plus Anti-PD-1 in Esophageal Squamous Cell Carcinoma
A new serum cytokine-based risk score (CYTOscore) utilizing IL-8, CCL3, and CCL4 identifies ESCC patients likely to benefit from chemoradiotherapy combined with toripalimab, offering a non-invasive tool for personalized immunotherapy and pr
Ethosuximide Fails to Relieve IBS-Related Abdominal Pain: Results from a Multicenter Randomized Controlled Trial
A multicenter RCT found that ethosuximide, a T-type calcium channel blocker, did not improve abdominal pain in IBS patients compared to placebo and was associated with significant tolerability issues, highlighting the need for more selectiv
Distinct Histological Patterns in Anal Canal Cancer: Insights from the Japanese National Registry
This article explores the unique epidemiological landscape of anal canal cancer in Japan, highlighting the predominance of adenocarcinoma over squamous cell carcinoma and the rising role of chemoradiotherapy in clinical management.
Personalizing Neoadjuvant Intensity: 5-Year CinClare Data Validate UGT1A1-Guided Irinotecan for Rectal Cancer
The 5-year update of the CinClare trial demonstrates that adding irinotecan to neoadjuvant chemoradiotherapy, guided by UGT1A1 genotype, significantly improves long-term survival and disease-free outcomes in patients with locally advanced r
Global Gastrointestinal Cancer Burden to Nearly Double by 2050: A Critical Call for Targeted Prevention and Resource Allocation
By 2050, global gastrointestinal cancer incidence is projected to surge by 85%, reaching 9.06 million cases annually. While gastric cancer rates are declining, colorectal and pancreatic cancers are rising sharply, particularly in low and me
Adjuvant Camrelizumab plus Capecitabine Extends Recurrence-Free Survival in Resected Intrahepatic Cholangiocarcinoma: Results from the Phase 2 ACC Trial
The Phase 2 ACC trial demonstrates that adjuvant camrelizumab combined with capecitabine achieves a median recurrence-free survival of 24.29 months for patients with resected intrahepatic cholangiocarcinoma, offering a promising and managea
Tinengotinib Offers a Potential Breakthrough for FGFR-Inhibitor Resistant Cholangiocarcinoma
A Phase 2 trial demonstrates that tinengotinib, a multi-kinase inhibitor, shows significant clinical activity in patients with advanced cholangiocarcinoma who have progressed on prior FGFR inhibitors, particularly those with acquired resist
Pemvidutide Demonstrates Robust MASH Resolution in IMPACT Phase 2b Trial: Clinical Implications of Dual GLP-1/Glucagon Agonism
The 24-week results of the IMPACT trial show that pemvidutide significantly improves MASH resolution without worsening fibrosis. While fibrosis improvement did not reach significance at this early time point, the drug’s safety profile and m
Dual Agonism for MASH: Pemvidutide Achieves Rapid Histological Resolution in Phase 2b IMPACT Trial
The Phase 2b IMPACT trial demonstrates that pemvidutide, a GLP-1/glucagon dual agonist, significantly achieves MASH resolution at 24 weeks without dose titration, though fibrosis improvement did not reach significance at this early timepoin
Beyond Conventional Immunotherapy: Zhenqi Fuzheng Granule Synergizes with PD-1 Blockade by Remodeling Gut-Immune Metabolism in Colorectal Cancer
Researchers have discovered that Zhenqi Fuzheng Granule enhances PD-1 antibody efficacy in colorectal cancer by modulating the gut microbiota-SCFA-GPR109A axis, effectively suppressing tumor glycolysis and reversing immune exhaustion within
HER2-Positivity in Advanced Biliary Tract Cancer: A Dual Role as a Negative Prognostic Factor and a Potent Therapeutic Vulnerability
A multi-institutional analysis reveals that HER2-positivity in advanced biliary tract cancer signals a poorer prognosis but offers a significant survival benefit when targeted with anti-HER2 therapies, advocating for routine screening and s
Browse by specialty
Open language-specific specialty feeds and department pages.